Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EBIO: Epoch Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (6)	12/28/2000 3:57:33 PM
From: JR	Read Replies (1) \| Respond to of 33

Tuck, could you elaborate on the specifics of the Trega take-out price. Thanks. What are the specific downward revisions in earnings for EBIO? Are they significant...that much so to value the company at $4-5/shar3? I think we're seeing people selling into the year-end taxloss season in addition to a market not willing to pay for early stage company without earnings. Sad thing is, the management went out of their way to position the acquisition as a positive indication about the probe business for 2001 and future.